Option chain shows key data for NeuroBo Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NeuroBo Pharmaceuticals.

NeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock, Option Chain

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Penny,Stock,Investments,Taking,Off,Concept

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

NANX

NRBO

NUVB

NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

Wegovy

Biotech

Health Care

Movers

General

NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide.

NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success

Earnings

Eurozone

Commodities

Small Cap

Global

Intraday Update

CELU

CMPR

PTON

REVB

VLCN

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday.

The Dow traded up 0.66% to 38,403.91 while the NASDAQ rose 1.01% to 15,316.80. The S&amp;P 500 also rose, gaining, 0.87% to 4,887.70.

Dow Jumps 250 Points; Honeywell Issues Weak Forecast

NeuroBo Pharmaceuticals, Inc. - Common Stock

NeuroBo Pharmaceuticals Inc

Jason McCarthy, an analyst from Maxim Group, reiterated the Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report). The associated price ta...

Buy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental Pipeline

NeuroBo Pharmaceuticals GAAP EPS of -$1.85

NeuroBo Pharmaceuticals ( ($NRBO) ) just unveiled an update. NeuroBo Pharmaceuticals, Inc. has announced promising results from Part 1 of the Phase...

NeuroBo's DA-1726 Shows Promise in Obesity Trial Phase 1

An announcement from NeuroBo Pharmaceuticals ( ($NRBO) ) is now available. NeuroBo Pharmaceuticals, Inc. has updated its corporate presentation on ...

NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

NeuroBo Pharmaceuticals GAAP EPS of -$0.55 beats by $0.18

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report). The associated price ta...

NeuroBo Pharmaceuticals: Promising MASH and Obesity Treatment Pipeline Driving Buy Rating

NeuroBo Pharmaceuticals (NRBO) announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia ...

NeuroBo Pharmaceuticals announces relignment, change name

NeuroBo Pharmaceuticals ( ($NRBO) ) just unveiled an update. NeuroBo Pharmaceuticals is set to rebrand as MetaVia Inc. on November 29, 2024, with a...

NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report), retaining the price target of $1...

NeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthy

ADBE

ALLY

BLNK

BYDDF

CAPR

CTRI

CYTK

IBTA

INTC

LNVGY

MIRM

MSFT

MTEN

NAPA

NFLX

NVDA

NVNO

OCGN

OKTA

QCOM

SCHW

SERV

SFHG

SRRK

TSLA

ULTA

USGO

VANI

VLKAF

VRSSF

Press Releases

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Comments

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals (NRBO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga